DOCSLIB.ORG

Lymphoscintigraphy and Sentinel Nodes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lymphoscintigraphy and Sentinel Nodes CONTINUING EDUCATION Lymphoscintigraphy and Sentinel Nodes Valeria M. Moncayo1, John N. Aarsvold1,2, and Naomi P. Alazraki1,2 1Emory University School of Medicine, Atlanta, Georgia; and 2VA Medical Center, Atlanta, Georgia Learning Objectives: On successful completion of this activity, participants should be able to describe (1) generic fundamentals of lymphoscintigraphy procedures of sentinel lymph node biopsy (SLNB) protocols; (2) specific injection and imaging components of SLNB protocols used in the management of patients with breast cancer, melanoma, and head and neck malignancies; and (3) specific indications of breast cancer, melanoma, and head and neck malignancies that suggest inclusion of a SLNB in the management of a patient. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through June 2018. the goal. We discuss SLN procedures that include lymphoscintigraphy It has been validated that sentinel lymph node biopsy (SLNB) shows in the setting of malignancies to the skin, breast, and head and neck. whether a patient’s breast cancer or melanoma has spread to re- gional lymph nodes. As a result, management of patients with these cancers has been revolutionized. SLNB has replaced axillary lymph LYMPHOSCINTIGRAPHY IN SLN PROCEDURES node dissection (ALND) as the staging modality of choice for early breast cancer and has replaced complete lymph node dissection as Lymphoscintigraphy for identifying and localizing SLNs has the staging modality of choice for melanoma in patients whose emerged over the past 2 decades as the staging modality of choice for SLNBs indicate no metastases. Recently concluded multicenter, breast cancers and melanomas that are clinically node-negative (1–3). randomized trials for breast cancer with 5- to 10-y outcome data SLNs are regional nodes that directly receive lymph drainage from have shown no significant differences in disease-free survival rates the primary tumor. If the first lymph node draining a tumor is neg- or overall survival rates between SLNB and ALND groups but have ative for malignant cells, there is a high probability that the remaining shown significantly lower morbidity with SLNB than with ALND. The lymph nodes in the relevant primary and subsequent basins will also lowest false-negative rates (5.5%–6.7%) were seen in studies that be negative (4). Removing only SLNs eliminates the need for a full used preoperative lymphoscintigraphy and dual mapping during lymphadenectomy, reduces associated adverse effects, and usually surgery. To assess the survival impact of SLNB in melanoma, the results in a better quality of life. There may be several SLNs in Multicenter Selective Lymphadenectomy Trial I was performed. Melanoma-specific survival rates were not different between sub- a patient, as there may be drainage in multiple directions from the jects randomized to SLNB with lymphadenectomy for nodal metas- primary lesion. In the case of multiple nodes, the nodes that dem- tasis on biopsy and subjects randomized to observation with lym- onstrate significant radiotracer uptake may all or individually also phadenectomy for nodal relapse. However, the 10-y disease-free accumulate metastatic cells; therefore, these should be surgically survival rates were better for the SLNB group than for the observa- removed and tested for metastatic cells. tion group, specifically among patients with intermediate-thickness Cabanas, a urologist, introduced SLN biopsy (SLNB) in the melanomas or thick melanomas. management of penile cancer (5). In the 1990s, Morton et al. de- Key Words: lymphoscintigraphy; sentinel lymph node; breast cancer; veloped and applied SLNB in the management of patients with mel- melanoma anoma and breast cancer. These protocols used a dye that stains lymph J Nucl Med 2015; 56:901–907 vessels and sentinel nodes blue to make them visible (3). Also in the DOI: 10.2967/jnumed.114.141432 1990s, Alex et al. introduced SLNB based on radiotracer techniques. These radiotracer techniques depend on detecting the radiotracer g emissions using a g-counting probe or a g camera (2). Lymphoscin- tigraphy is the dynamic or static imaging of the transit of radiotracer from tumors to SLNs. The imaging often allows a surgeon to easily Lymphoscintigraphy refers to planar or tomographic imaging identify and perform a biopsy of SLNs. of a radioisotope in lymphatics, usually 99mTc. Identification and During the years since the initial demonstrations of SLNB localization of all sentinel lymph nodes (SLNs) for surgical biopsy is protocols, many investigative studies have supported the use of SLNB as a highly reliable method for screening axillary and extraaxillary nodes in early (stages I and II) breast cancer. In the management of Received Mar. 3, 2015; revision accepted Apr. 23, 2015. early breast cancer, SLNB has replaced the more invasive axillary For correspondence or reprints contact: Valeria M. Moncayo, Division of lymph node dissection (ALND). In melanoma, lymphoscintigraphy Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, 1364 Clifton Rd. NE, 1st provides a means of localizing SLNs to a specific regional drainage Floor, #D118, Atlanta, GA 30322. area or to multiple regional drainage areas. SLNB has undergone E-mail: [email protected] refinement and improvement since the first protocols were reported. Published online Apr. 30, 2015. COPYRIGHT © 2015 by the Society of Nuclear Medicine and Molecular SLNB is now widely accepted and used in breast cancer and Imaging, Inc. melanoma (6) and has been evaluated for potential application to other LYMPHOSCINTIGRAPHY AND SENTINEL NODES • Moncayo et al. 901 malignancies. We discuss SLNB primarily in the context of breast SLNs, particularly internal mammary SLNs, a protocol should include cancer and melanoma but also remark on its status for head and neck peritumoral injections (14). Administering peritumoral injections malignancies. requires more information about the exact location of the tumor than Evidence of the attention to, enthusiasm for, and indeed success does administering superficial injections. Also, if there has been an of this procedure in aiding management of various cancers is excisional biopsy, or if there is a prosthesis, care must be taken not to apparent from a Google search for “sentinel1node” that generated inject into the dead space of a seroma or into the prosthesis (10,15). over 500,000 hits and from a PubMed search for “(sentinel) AND node” that generated over 10,000 investigative and educational Imaging publications on SLN topics in peer-reviewed journals. In melanoma, depending on the location of the primary tumor, imaging must cover all possible drainage sites. For example, if the Procedure for SLN Lymphoscintigraphy primary tumor is on a patient’s trunk, imaging of the left and right The SLNB procedure requires minimal to no preparation on the axillary and neck regions as well as the left and right pelvis and part of the patient. Some centers use topical lidocaine and prilocaine inguinal regions must be performed (Fig. 1). For extremity tumors, cream (EMLA; AstraZeneca) to reduce the pain of needle puncture. imaging of the axillary and antecubital regions (upper-extremity Patients who are encouraged to use the cream are instructed on tumors) or of the inguinal and popliteal regions (lower-extremity where and how to apply it to unbroken skin. They are asked to do tumors) must be performed. For head and neck squamous cell this a minimum of 30 min before the procedure (7). At the clinic, carcinoma, the entire head and neck must be imaged. In particular, patients wear a gown after removal of all jewelry and clothing that all locations distal to the tumor must be imaged, as lymph drain- might negatively affect the lymphoscintigraphy image. age is generally caudad. Also, for head and neck SLN procedures, After lymphoscintigraphy, the physician responsible for the practitioners should always keep in mind that many structures in injection and imaging procedure communicates directly with the the head and neck are small and vital. Drainage across the body surgeon, and the communications are documented. At the time of midline is common after injections in the trunk and in the head surgery, the surgeon has access to the images. and neck (Fig. 2) (16). In addition, for some indications SPECT or Radiopharmaceuticals and Injection Parameters SPECT/CT may be preferred. Radiopharmaceuticals used for lymphoscintigraphy include All aspects of the imaging procedure, including skin marking, 99mTc-pertechnetate–labeled colloids (particles range from 3 to should be performed with the patient positioned as during surgery. 5,000 nm and are often filtered to a narrow size range) and Dynamic Imaging. In melanoma patients, dynamic imaging 99mTc-tilmanocept (Lymphoseek; Navidea [mannosyl diethylene- begins as soon as the injections are complete. Particularly for head triaminepentaacetic acid (DTPA) dextran]).
Load more

Recommended publications
  • Sporadic (Nonhereditary) Colorectal Cancer: Introduction
    Sporadic (Nonhereditary) Colorectal Cancer: Introduction Colorectal cancer affects about 5% of the population, with up to 150,000 new cases per year in the United States alone. Cancer of the large intestine accounts for 21% of all cancers in the US, ranking second only to lung cancer in mortality in both males and females. It is, however, one of the most potentially curable of gastrointestinal cancers. Colorectal cancer is detected through screening procedures or when the patient presents with symptoms. Screening is vital to prevention and should be a part of routine care for adults over the age of 50 who are at average risk. High-risk individuals (those with previous colon cancer , family history of colon cancer , inflammatory bowel disease, or history of colorectal polyps) require careful follow-up. There is great variability in the worldwide incidence and mortality rates. Industrialized nations appear to have the greatest risk while most developing nations have lower rates. Unfortunately, this incidence is on the increase. North America, Western Europe, Australia and New Zealand have high rates for colorectal neoplasms (Figure 2). Figure 1. Location of the colon in the body. Figure 2. Geographic distribution of sporadic colon cancer . Symptoms Colorectal cancer does not usually produce symptoms early in the disease process. Symptoms are dependent upon the site of the primary tumor. Cancers of the proximal colon tend to grow larger than those of the left colon and rectum before they produce symptoms. Abnormal vasculature and trauma from the fecal stream may result in bleeding as the tumor expands in the intestinal lumen.
    [Show full text]
  • Paraneoplastic Neurologic Syndromes
    DO I:10.4274/tnd.05900 Turk J Neurol 2018;24:63-69 Case Report / Olgu Sunumu Paraneoplastic Neurologic Syndromes: Rare But More Common Than Expected Nine Cases with a Literature Review Paraneoplastik Nörolojik Sendromlar: Nadir Ancak Beklenenden Daha Sık Dokuz Olgu ile Literatür Derlemesi Hülya Uluğut Erkoyun, Sevgin Gündoğan, Yaprak Seçil, Yeşim Beckmann, Tülay Kurt İncesu, Hatice Sabiha Türe, Galip Akhan Izmir Katip Celebi University, Atatürk Training and Research Hospital, Department of Neurology, Izmir, Turkey Abstract Paraneoplastic neurologic syndromes (PNS) are rare disorders, which are remote effects of cancer that are not caused by the tumor, its metastasis or side effects of treatment. We had nine patients with PNS; two of our patients had limbic encephalitis, but one had autoimmune limbic encephalitis with no malignancy; two patients had subacute cerebellar degeneration; three had Stiff-person syndrome; one had Lambert-Eaton myasthenic syndrome; and the remaining patient had sensory neuronopathy. In most patients, the neurologic disorder develops before the cancer becomes clinically overt and the patient is referred to a neurologist. Five of our patients’ malignancies had been diagnosed in our clinic after their neurologic symptoms became overt. PNS are more common than expected and neurologists should be aware of the variety of the clinical presentations of these syndromes. When physicians suspect PNS, cancer screening should be conducted. The screening must continue even if the results are negative. Keywords: Paraneoplastic, neurologic syndromes, neurogenic autoantibodies Öz Paraneoplastik nörolojik sendromlar (PNS), kanserin doğrudan, metastaz ya da tedavi yan etkisine bağlı olmayan, uzak etkisi ile ortaya çıkan nadir hastalıklardır. Dokuz PNS’li hastanın ikisi limbik ensefalitti fakat bunlardan biri otoimmün limbik ensefalitti ve malignitesi yoktu.
    [Show full text]
  • Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents
    cancers Review Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents Roberta Balestrino 1,* , Roberta Rudà 2,3 and Riccardo Soffietti 3 1 Department of Neuroscience, University of Turin, Via Cherasco 15, 10121 Turin, Italy 2 Department of Neurology, Castelfranco Veneto/Treviso Hospital, Via dei Carpani, 16/Z, 31033 Castelfranco Veneto, Italy; [email protected] 3 Department of Neuro-Oncology, University of Turin, Via Cherasco 15, 10121 Turin, Italy; riccardo.soffi[email protected] * Correspondence: [email protected] Received: 13 October 2020; Accepted: 9 November 2020; Published: 12 November 2020 Simple Summary: Brain metastases (BMs) are the most common intracranial tumours in adults and occur up to 3–10 times more frequently than primary brain tumours. In up to 15% of patients with BM, the primary tumour cannot be identified. These cases are known as BM of cancer of unknown primary (CUP) (BM-CUP). The understanding of BM-CUP, despite its relative frequency and unfavourable outcome, is still incomplete and clear indications on management are missing. The aim of this review is to summarize current evidence on the diagnosis and treatment of BM-CUP. Abstract: Brain metastases (BMs) are the most common intracranial tumours in adults and occur up to 3–10 times more frequently than primary brain tumours. BMs may be the cause of the neurological presenting symptoms in patients with otherwise previously undiagnosed cancer. In up to 15% of patients with BMs, the primary tumour cannot be identified. These cases are known as BM of cancer of unknown primary (CUP) (BM-CUP).
    [Show full text]
  • Carcinogenesis
    Chapter 3 Chapter 3 Carcinogenesis CONTENTS Oral Carcinoma and Smokeless Tobacco Use: A Clinical Profile W. Frederick McGuirt and Anna Wray .................................................. 91 Introduction .................................................................................... 91 Patients ............................................................................................ 91 Field Cancerization ......................................................................... 92 Discussion........................................................................................ 93 References ........................................................................................ 95 Chemical Composition of Smokeless Tobacco Products Klaus D. Brunnemann and Dietrich Hoffmann ..................................... 96 Introduction .................................................................................... 96 Chemical Composition ................................................................... 97 Carcinogenic Agents in ST .............................................................. 97 Carcinogenic N-Nitrosamines ....................................................... 100 TSNA .............................................................................................. 101 Control of Carcinogens in ST ....................................................... 104 References ...................................................................................... 106 Carcinogenesis of Smokeless Tobacco Dietrich Hoffmann, Abraham
    [Show full text]
  • Paraneoplastic Syndromes in Lung Cancer and Their Management
    359 Review Article Page 1 of 9 Paraneoplastic syndromes in lung cancer and their management Asad Anwar1, Firas Jafri1, Sara Ashraf2, Mohammad Ali S. Jafri3, Michael Fanucchi3 1Department of Internal Medicine, Westchester Medical Center, Valhalla, NY, USA; 2Department of Hematology/Oncology, Marshall University, Huntington, WV, USA; 3Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Mohammad Ali S. Jafri, MD. Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA. Email: [email protected]. Abstract: Paraneoplastic syndromes are most frequently associated with lung cancer. This review considers a variety paraneoplastic syndromes associated with lung cancer and discusses their pathophysiology, clinical features and management options. Keywords: Paraneoplastic syndromes; lung cancer; thoracic oncology Submitted Feb 12, 2019. Accepted for publication Apr 25, 2019. doi: 10.21037/atm.2019.04.86 View this article at: http://dx.doi.org/10.21037/atm.2019.04.86 Introduction PTHrP production (parathyroid hormone related-protein), it is referred to as HHM. Paraneoplastic syndromes refer to the remote effects HHM is observed in a variety of malignancies such as associated with malignancy which are unrelated to direct breast, renal, multiple myeloma and lung; squamous cell tumor invasion or metastases (1). These may occur before is the most frequently observed subtype (3-5). Osteolytic the cancer is diagnosed and can be independent in their metastases are another significant cause of hypercalcemia in severity to the stage of the primary tumor.
    [Show full text]
  • Primary Brain Tumors in Adults: Diagnosis and Treatment
    Primary Brain Tumors in Adults: Diagnosis and Treatment ALLEN PERKINS, MD, MPH, University of South Alabama, Mobile, Alabama GERALD LIU, MD, Harvard Vanguard Medical Associates, Weymouth, Massachusetts Primary intracranial tumors of the brain structures, including meninges, are rare with an overall five-year survival rate of 33.4%; they are collectively called primary brain tumors. Proven risk factors for these tumors include certain genetic syndromes and exposure to high-dose ionizing radiation. Primary brain tumors are classified by histopathologic criteria and immunohistochemical data. The most common symptoms of these tumors are headache and seizures. Diagnosis of a suspected brain tumor is dependent on appropriate brain imaging and histopathology. The imaging modality of choice is gadolinium-enhanced magnetic resonance imaging. There is no specific pathognomonic feature on imaging that differ- entiates between primary brain tumors and metastatic or nonneoplastic disease. In cases of suspected or pathologically proven metastatic disease, chest and abdomen computed tomography may be helpful, although determining the site of the primary tumor is often difficult, especially if there are no clinical clues from the history and physical examination. Using fluorodeoxyglucose positron emission tomography to search for a primary lesion is not recommended because of low specificity for differentiating a neoplasm from benign or inflammatory lesions. Treatment decisions are individu- alized by a multidisciplinary team based on tumor type and location, malignancy potential, and the patient’s age and physical condition. Treatment often includes a combination of surgery, radiotherapy, and chemotherapy. After crani- otomy, patients should be followed closely for complications, including deep venous thrombosis, pulmonary embolism, intracranial bleeding, wound infection, systemic infection, seizure, depression, worsening neurologic status, and adverse drug reaction.
    [Show full text]
  • Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-Type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 21
    [C'ANC'ER K|-:S|-:AKC|| SS. .«SU-MM. September 15, l")95| Advances in Brief Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 21 B. Schmalfeldt,- W. Kühn,U. Reuning, L. Pache, P. Dettmar, M. Se-limiti, F. Jänicke, H. Höfler,and H. Graeff Frauenklinik der Technischen Universität München. Klinikum rechts tier Isar. Ismaninger Strasse 22. D-KI675. Munich ¡B.S.. W. K., U. R., L P.. M. S., F. J., H. G.I. and Institut fürAllgemeine Pathologie und Pathologische Anatomie, Technische Universität München¡P.D., H. H. I, Munich, Germany Abstract metastasis is controlled by a series of successive events. After local proteolysis of the surrounding extracellular matrix, detachment and The relevance of urokinase-type plasminoceli activator (uPA) and plas- spread of tumor cells is facilitated followed by the invasion of the minogen activator inhibitor (PAI) type I in predicting the survival prob adjacent tissue, crossing of tissue boundaries and the basement mem ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has brane. Intravasation and extravasation are followed by reimplantation recently been shown by us (W. Kühnelal., Gynecol. Oncol., 55: 401-409, of tumor cells into the respective target organ, remodeling of a new 1994). In the present study, we determined uPA, uPA receptor, PAI-1, and tumor stroma, and angiogenesis in order to consolidate a secondary PAI-2 concentrations in primary tumors and tumor-infiltrated omentum tumor at a distant locus.
    [Show full text]
  • Guidelines for Breast Screening
    Frequently Asked Questions about Mammography and the USPSTF Recommendations: A Guide for Practitioners Wendie A. Berg, MD, PhD, FACR1, R. Edward Hendrick, PhD, FACR2, Daniel B. Kopans, MD, FACR3, and Robert A. Smith, PhD4 1American Radiology Services, Johns Hopkins Green Spring, Lutherville, MD 21093, [email protected]; 2Department of Radiology, University of Colorado, Denver, CO, [email protected]; 3Department of Radiology, Massachusetts General Hospital, Harvard University School of Medicine, Boston, MA, [email protected]; 4 Cancer Control Sciences Department, American Cancer Society, Atlanta, GA, [email protected]. What is the goal of breast cancer screening? The goal is to reduce deaths due to breast cancer by detecting breast cancer early, when treatment is more effective and less harmful. Simply put, the goal of breast cancer screening is to reduce the incidence of advanced disease. Breast cancer has to reach a certain size to be detected. The benefit of screening mammography is earlier detection and lower risk that the breast cancer will have spread at the time of detection [1]. If a woman waits for her breast cancer to become evident as a palpable lump detected by her or her primary care physician, it will be larger and more likely to have spread to her lymph nodes or elsewhere at the time of detection. This is especially true for premenopausal women. Breast cancers found with high-quality, two-view screening mammography are relatively small, with median size 1.0 to 1.5 cm (0.4 to 0.6 inches, or the size of a small marble) [2]. Approximately 10% of invasive cancers 1 cm in size or smaller have spread to lymph nodes at the time of detection, compared to close to 35% of those 2 cm in size and 60% of those 4 cm or larger in size [3].
    [Show full text]
  • (NCCN) Breast Cancer Clinical Practice Guidelines
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 5.2020 — July 15, 2020 NCCN.org NCCN Guidelines for Patients® available at www.nccn.org/patients Continue Version 5.2020, 07/15/20 © 2020 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 5.2020 Table of Contents Breast Cancer Discussion *William J. Gradishar, MD/Chair ‡ † Sharon H. Giordano, MD, MPH † Sameer A. Patel, MD Ÿ Robert H. Lurie Comprehensive Cancer The University of Texas Fox Chase Cancer Center Center of Northwestern University MD Anderson Cancer Center Lori J. Pierce, MD § *Benjamin O. Anderson, MD/Vice-Chair ¶ Matthew P. Goetz, MD ‡ † University of Michigan Fred Hutchinson Cancer Research Mayo Clinic Cancer Center Rogel Cancer Center Center/Seattle Cancer Care Alliance Lori J. Goldstein, MD † Hope S. Rugo, MD † Jame Abraham, MD ‡ † Fox Chase Cancer Center UCSF Helen Diller Family Case Comprehensive Cancer Center/ Comprehensive Cancer Center Steven J. Isakoff, MD, PhD † University Hospitals Seidman Cancer Center Massachusetts General Hospital Amy Sitapati, MD Þ and Cleveland Clinic Taussig Cancer Institute Cancer Center UC San Diego Moores Cancer Center Rebecca Aft, MD, PhD ¶ Jairam Krishnamurthy, MD † Karen Lisa Smith, MD, MPH † Siteman Cancer Center at Barnes- Fred & Pamela Buffet Cancer Center The Sidney Kimmel Comprehensive Jewish Hospital and Washington Cancer Center at Johns Hopkins University School of Medicine Janice Lyons, MD § Case Comprehensive Cancer Center/ Mary Lou Smith, JD, MBA ¥ Doreen Agnese, MD ¶ University Hospitals Seidman Cancer Center Research Advocacy Network The Ohio State University Comprehensive and Cleveland Clinic Taussig Cancer Institute Cancer Center - James Cancer Hospital Hatem Soliman, MD † and Solove Research Institute P.
    [Show full text]
  • Sentinel Lymph Brochure
    A WOMAN’S GUIDE TO BREAST HEALTH Answers to Your Questions Commonly Used Terms Q. What is the sentinel lymph node? Axillary — Pertaining to the area under the arm, including the lymph nodes. A. The sentinel lymph node is the first node(s) in the body to come in contact with the cancer cells as they leave the Benign — Non-cancerous. primary tumor in the breast and start to spin off or spread False Negative — Test indicates that the area is “normal” into the rest of the body’s tissues. even though cancer is really there. Q. What are the benefits of sentinel lymph node biopsy? Invasive Cancer — Cancer that has spread to nearby A. Removing only the sentinel node allows the pathologist tissue. Invasive cancer is also called infiltrating cancer or infiltrating carcinoma. (a physician specializing in the study of disease) to closely examine the specimen, aiding in the detection of cancer. Lymphedema — A condition in which excess fluid collects There is typically a smaller incision, which may result in in tissue and causes swelling. It may occur in the arm after lymph vessels or lymph nodes in the underarm shorter recovery time and less post-operative pain than are removed. axillary lymph node dissection. Q. Lymph Nodes — Small, bean-shaped structures found Who is a candidate for sentinel lymph node biopsy? in the body that trap and remove cell waste and help fight A. Women who have undergone a breast biopsy and have infections. They are often examined to determine if cancer been diagnosed with invasive breast cancer should ask has spread.
    [Show full text]
  • Cancer Prevention and Control.Indd
    COMMENTARY Cancer Prevention and Control Then and Now Patricia A. Ganz, UCLA Jonsson Comprehensive Cancer Center October 22, 2018 Controlling or reducing the risk for cancer was a prin- obstruction of the drainage system from the kidneys. cipal goal of the National Cancer Act, signed by Presi- While radical hysterectomy is still performed today, dent Nixon in 1971. Long before the human genome the exenteration surgical procedure was abandoned was sequenced, and the etiology of many cancers was due to its extreme morbidity and failure to prevent understood, Americans were determined to fi nd a way both local and distant metastatic disease. to reduce the burden of cancer in the population. The Today, we understand that almost all cervical cancer act was passed only seven years after the fi rst US Sur- results from infection with oncogenic serotypes of HPV geon General’s report on the health consequences of that are sexually transmitted. Pap smears are still per- cigarettes and smoking. As we approach the 50th year formed, but at less frequent intervals. Testing for high- since the War on Cancer began, it is helpful to refl ect on risk HPV DNA can be conducted instead, or co-testing past and current cancer prevention and control. This can be performed [2]. There are several highly eff ec- paper focuses on 1) early detection and prevention of tive vaccines that protect against HPV infection. Active cancer and 2) cancer survivorship, areas highlighted in campaigns are underway to immunize all pre-teenage the recent Lancet Oncology Commission report on fu- girls and boys, although uptake has been lower than ture cancer research priorities in the United States [1].
    [Show full text]
  • Overview of Patients with Multiple Primary Tumors During Eighty-Four
    Original Investigation/Orijinal Araştırma İstanbul Med J 2019; 20(4): 294-8 DO I: 10.4274/imj.galenos.2019.32815 Overview of Patients with Multiple Primary Tumors During Eighty-four Months Follow-up: A Single Center Experience Seksen-dört Aylık İzlemde Çoklu Primer Tümör Tanılı Hastalarımıza Bakış: Tek Merkez Deneyimi Özlem Mermut1, Rıza Umar Gürsu2 1İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey 2İstanbul Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey ABSTRACT ÖZ Introduction: Advances in oncological diagnosis and treatment Amaç: Onkolojik tanı ve tedavilerdeki gelişmeler sağkalımı increase survival and remission of the disease. However, artırmakta ve hastalığın remisyonunu sağlamaktadır. Bununla prolonged survival also increases the likelihood of developing birlikte uzamış sağkalım ikincil primer malignitelerin gelişmesi second primary malignancies. The aim of this article was to olasılığını da artırmaktadır. Bu makalenin amacı kanser tanısı evaluate whether the second primary tumor is associated with konulmuş, tedavi almış ve takip edilen hastalarda ikinci the first primary tumor and to determine the survival time tümörün birinci tümörle ilişkili olup olmadığını ve sağkalım in patients diagnosed with cancer, treated, and followed-up, sürelerini değerlendirmek, bu hastaların takibinde neler and to make recommendations about the follow-up of these yapılabileceği konusunda önerilerde bulunmaktır. patients. Yöntemler: Ocak 2011 ile Aralık 2017 tarihleri arasında, Methods: Patients who were admitted to the İstanbul Training İstanbul Eğitim ve Araştırma Hastanesi Radyasyon Onkolojisi and Research Hospital, Clinic of Radiation Oncology and Medical Oncology, between January 2011 and December ve Tıbbi Onkoloji polikliniklerine başvuran, 6 aydan uzun süreli 2017, and who had a follow-up of more than 6 months were takipleri olan, 9892 hasta dosyası retrospektif olarak incelendi.
    [Show full text]